Yen-Wen Liu
Overview
Explore the profile of Yen-Wen Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
1723
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen S, Fang Y, Huang C, Wu J, Shan Y, Liu Y, et al.
Sci Data
. 2024 Dec;
11(1):1378.
PMID: 39695135
Cardiac regenerative therapy has recently progressed by reprogramming somatic cells into induced pluripotent stem cells (iPSCs) and advanced by large-scale differentiation-derived cardiomyocytes (hiPSC-CMs). However, repairing damaged cardiac tissues with hiPSC-CMs...
2.
Yu L, Liu Y, Chou T, Liu Y, Su P, Liu P
Rev Cardiovasc Med
. 2024 Jul;
23(7):242.
PMID: 39076927
Background: Atrial fibrillation (AF) is associated with an increased risk of heart failure, death and thromboembolism. AF is prevalent in patients with cancer. Although current guidelines suggest the application of...
3.
Chang H, Hsu H, Fang Y, Liu P, Liu Y
Biomed Pharmacother
. 2024 May;
176:116759.
PMID: 38788603
Background: Sodium-glucose cotransporter-2 inhibitors, such as empagliflozin, are pivotal therapies for heart failure. However, the effect of empagliflozin on doxorubicin-related cardiac dysfunction remains unclear. Methods: Human induced pluripotent stem cell-...
4.
Liu Y, Tang C
Nurs Res
. 2024 Jan;
73(2):158-165.
PMID: 38193910
Background: The outbreak of COVID-19 caused severe damage to public health globally and served as a stark reminder of the potential for future pandemics. Promoting protective behaviors to prevent the...
5.
Chen H, Liu Y, Chang K, Wu Y, Chen Y, Chao Y, et al.
Nat Commun
. 2023 Nov;
14(1):7249.
PMID: 37945565
The gut microbiome and its metabolites are increasingly implicated in several cardiovascular diseases, but their role in human myocardial infarction (MI) injury responses have yet to be established. To address...
6.
Cheng Y, Hsieh M, Lin C, Chang C, Huang C, Puntney R, et al.
Circulation
. 2023 Sep;
148(18):1395-1409.
PMID: 37732466
Background: Remuscularization of the mammalian heart can be achieved after cell transplantation of human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes (CMs). However, several hurdles remain before implementation into clinical practice....
7.
Fang Y, Wang S, Liao I, Tsai K, Huang P, Yang P, et al.
Adv Healthc Mater
. 2023 Sep;
12(29):e2301186.
PMID: 37672681
Although human pluripotent stem cells (hPSCs)-derived cardiomyocytes (hPSC-CMs) can remuscularize infarcted hearts and restore post-infarct cardiac function, post-transplant rejection resulting from human leukocyte antigen (HLA) mismatching is an enormous obstacle....
8.
Hsu Y, Huang M, Chang H, Lee C, Chen D, Li Y, et al.
BMC Geriatr
. 2023 Jul;
23(1):443.
PMID: 37468836
Background: The second-and third-generation drug-eluting stents (DESs) in-stent restenosis (ISR) genetic risk score (GRS) model has been previously validated. However, the model has not been validated in geriatric patients. Therefore,...
9.
Chen Y, Masbuchin A, Fang Y, Hsu L, Wu S, Yen C, et al.
Biomed Pharmacother
. 2022 Nov;
157:113962.
PMID: 36370523
Background: Hepatocellular carcinoma (HCC) patients suffer varying degrees of heart dysfunction after tyrosine kinase inhibitor (TKI) treatment. Interestingly, HCC patients often have higher levels of pentraxin 3 (PTX3), and PTX3...
10.
Wang P, Fang Y, Liu Y, Yeh M
Biomedicines
. 2022 Nov;
10(11).
PMID: 36359284
The progress of medical technology and scientific advances in the field of anticancer treatment have increased the survival probabilities and duration of life of patients. However, cancer-therapy-induced cardiac dysfunction remains...